Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros












Base de datos
Intervalo de año de publicación
1.
EBioMedicine ; 86: 104353, 2022 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-36375317

RESUMEN

BACKGROUND: The E2F family of transcription factors play a crucial role in the development of various cancers. However, E2F members lack targetable binding pockets and are typically considered "undruggable". Unlike canonical small-molecule therapeutics, molecular glues mediate new E3 ligase-protein interactions to induce selective proteasomal degradation, which represents an attractive option to overcome these limitations. METHODS: Human proteome microarray was utilized to identify a natural product-derived molecular glue for targeting E2F2 degradation. Co-IP analysis with stable isotope labeling of amino acids in cell culture (SILAC)-based quantitative proteomics was carried out to further explore the E3 ligase for E2F2 degradation. FINDINGS: In this study, we identified a molecular glue bufalin, which significantly promoted E2F2 degradation. Unexpectedly, E2F2 underwent ubiquitination and proteasomal degradation via a previously undisclosed atypical E3 ligase, zinc finger protein 91 (ZFP91). In particular, we observed that bufalin markedly promoted E2F2-ZFP91 complex formation, thereby leading to E2F2 polyubiquitination via K48-linked ubiquitin chains for degradation. E2F2 degradation subsequently caused transcriptional suppression of multiple oncogenes including c-Myc, CCNE1, CCNE2, MCM5 and CDK1, and inhibited hepatocellular carcinoma growth in vitro and in vivo. INTERPRETATION: Collectively, our findings open up a new direction for transcription factors degradation by targeting atypical E3 ligase ZFP91. Meanwhile, the chemical knockdown strategy with molecular glue may promote innovative transcription factor degrader development in cancer therapy. FUNDING: This work was financially supported by the National Key Research and Development Project of China (2022YFC3501601), National Natural Sciences Foundation of China (81973505, 82174008, 82030114), and China Postdoctoral Science Foundation (2019M650396), the Fundamental Research Funds for the Central Universities.


Asunto(s)
Neoplasias , Ubiquitina-Proteína Ligasas , Humanos , Factor de Transcripción E2F2/efectos de los fármacos , Factor de Transcripción E2F2/metabolismo , Proteolisis , Factores de Transcripción/genética , Factores de Transcripción/metabolismo , Ubiquitina-Proteína Ligasas/metabolismo , Ubiquitinación
2.
Mol Cell Biol ; 30(2): 524-36, 2010 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-19917728

RESUMEN

The E2F transcription factors have emerged as critical apoptotic effectors. Herein we report that the E2F family member E2F3a can be induced by DNA damage through transcriptional and posttranslational mechanisms. We demonstrate that the posttranslational induction of human E2F3a is dependent on the checkpoint kinases. Moreover, we show that human E2F3a is a substrate for the checkpoint kinases (chk kinases) and that mutation of the chk phosphorylation site eliminates the DNA damage inducibility of the protein. Furthermore, we demonstrate that E2F1 and E2F2 are transcriptionally induced by DNA damage in an E2f3-dependent manner. Finally, using both in vitro and in vivo approaches, we establish that E2f3 is required for DNA damage-induced apoptosis. Thus, our data reveal the novel ability of E2f3 to function as a master regulator of the DNA damage response.


Asunto(s)
Apoptosis , Sistema Nervioso Central/metabolismo , Daño del ADN , Factor de Transcripción E2F3/metabolismo , Proteínas Quinasas/metabolismo , Animales , Antibióticos Antineoplásicos/farmacología , Antineoplásicos Fitogénicos/farmacología , Línea Celular , Línea Celular Tumoral , Sistema Nervioso Central/patología , Sistema Nervioso Central/efectos de la radiación , Quinasa 1 Reguladora del Ciclo Celular (Checkpoint 1) , Doxorrubicina/farmacología , Factor de Transcripción E2F1/efectos de los fármacos , Factor de Transcripción E2F1/metabolismo , Factor de Transcripción E2F2/efectos de los fármacos , Factor de Transcripción E2F2/metabolismo , Factor de Transcripción E2F3/agonistas , Factor de Transcripción E2F4/efectos de los fármacos , Factor de Transcripción E2F4/metabolismo , Factor de Transcripción E2F5/efectos de los fármacos , Factor de Transcripción E2F5/metabolismo , Etopósido/farmacología , Humanos , Ratones , Fosforilación/efectos de los fármacos , Fosforilación/fisiología , ARN Interferente Pequeño/metabolismo , Irradiación Corporal Total , Cinostatina/farmacología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...